Study of Tazemetostat in Lymphoid Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 5, 2024

Primary Completion Date

July 31, 2028

Study Completion Date

December 31, 2029

Conditions
T-cell Lymphoma
Interventions
DRUG

Tazemetostat

Treatment: On day 1 and day 15 of the first cycle, and day 1 of all following cycles, the subject will have office visit with physical exam, vital signs, and lab tests. The subject will take tazemetostat twice a day by mouth continuously as an outpatient. If continuing on the treatment for more than 6 cycles, visits change to every 3 months.

Trial Locations (1)

35294

RECRUITING

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER